|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Early Bird Tuition for Complex Peripheral Vascular Interventions Extended to July 31
Combining case-based learning — including review of your own cases — and simulation with the latest educational strategies SCAI's Complex Peripheral Vascular Interventions (CPVI) promises a fresh, innovative approach to your PVD education including:
Best yet, the early bird tuition rate for CPVI has been extended to Friday, July 31.
Case-based, intensive focus on aorto-iliac Intervention, SFA intervention and critical limb ischemia;
- Review of real cases starting weeks before the course;
- Small groups coming together to present, discuss and solve cases;
- Simulation training gives you a risk-free introduction to new techniques with experienced interventionalists on hand to offer tips and tricks;
- Focus on latest data and guidelines from those who produced them;
- Fun! This program will be interactive, social and unlike any other you've attended.
Enroll now and save!
SCAI gratefully acknowledges the following companies for their generous support of the SCAI Complex Peripheral Interventions course through educational grants while taking sole responsibility for all content developed and disseminated through this event.
- Silver sponsor: Medtronic, Terumo Interventional Systems
- Bronze sponsors: Abbott; AstraZeneca, Cook Medical
| Share this article:
Whether you are a healthcare professional, a patient or simply someone looking to know more about the complete solutions offered by Cordis, let us show you how our distinctive approach to working in partnership with you results in innovative interventional products and services to help support sustained patient outcomes.
SCAI, Specialty Medicine Partners Lauds House Passage of Bipartisan Bill on Healthcare Innovation
SCAI recently joined its Alliance of Specialty Medicine partners in thanking the U.S. House of Representatives for passing HR 6, the 21st Century Cures Act, a bipartisan effort to improve the discovery, development and delivery that support continued innovation in our healthcare system. The Alliance looks forward to continuing to work with the Senate as they craft language for their Innovation for Healthier Americans initiative.
Find out more about this bill.
Who Will You Nominate for the Next MSCAI Class?
The MSCAI designation was developed to recognize SCAI Fellows who have recognized by their peers as "having demonstrated excellence in Invasive/Interventional Cardiology over a career, manifested by a commitment to the highest levels of clinical care, innovation, publication and teaching." Once each year, a new group of Fellows will be awarded MSCAI status. SCAI Fellows may nominate themselves or be nominated by another SCAI Fellow. The 2015 online submission deadline is Oct. 31.
Nominate a colleague today!
View the current list of MSCAI.
GLIDESHEATH SLENDER® 5Fr and 7Fr!
The only family of unique thin-wall sheaths, offering radial access to more patients.
• Increase Your Radial Access Options
• Optimize Procedural Outcomes
• Preserve Arterial Function
*GLIDESHEATH SLENDER® is currently available in 6Fr.
©2015 Terumo Medical Corporation. All rights reserved.
All brand names are trademarks or registered trademarks of Terumo. TIS-694-06012015
Looking to Reduce Your Transradial PCI Learning Curve?
Researchers of a study published in Circulation concluded that adoption of the transradial PCI technique is related to issues concerning operator proficiency and the need to overcome the assumed learning curve.
The good news is that the learning curve is not as great as you'd imagine. Better yet, SCAI is here to help you tackle that learning curve with the launch of SCAI TRIP Online Curriculum.
Featuring the very best presentations from SCAI's popular Transradial Interventional Program (TRIP) Series, this all-new eLearning offering is available as a full course (eight CME credits) or by individual session (one CME credit each). You decide which sessions to take and when to take them based upon your busy schedule!
Whether you are starting a TRI program at your institution, simply looking to increase your proficiency or plan on tackling STEMI or peripheral procedures via radial access, this program will assist you in building on or expanding your skills.
Featuring the top transradial experts from throughout the U.S., this program will also demonstrate how transradial access can increase patient comfort and safety, lower bleeding complications and reduce healthcare costs. Other hot topics will include diagnostic and guide catheter selection.
Start tackling that learning curve today with TRIP Online Curriculum!
Image of the Week: Why Can't I Advance Through the Prior Stent?
Emmanouil Brilakis, MD, PhD, FSCAI, of Dallas VA Medical Center and UT Southwestern Medical Center, recently presented a case illustrating the use of OCT to answer a mystery presenting in a routine angiographic follow-up nine months after right coronary artery PCI. Take a look at this case and send us your feedback!
The SCAI Imaging Center is developed and maintained with the generous support of St. Jude Medical. SCAI gratefully acknowledges this support, while taking sole responsibility for all content developed and disseminated through this effort.
1 in 6 Americans Too Far From Lifesaving Heart Centers
Tens of millions of rural, poor and Hispanic Americans do not have timely access to a lifesaving heart procedure, a new study finds. Researchers analyzed the driving times for 306 million people to reach the closest angioplasty centers across the continental United States. The median time to an angioplasty center was 33 minutes, they found. However, the median travel time for more than 16 percent of the population — about 50 million people — was 81 minutes, according to the study.
The Vascular Team Approach: Getting a Leg Up on PAD With Education and Training
Interventional cardiologists are taking the lead in quality initiatives for peripheral artery disease revascularization. That includes developing guidelines, appropriate use criteria and promoting a vascular team model.
FDA Strengthens Warning of Heart Attack and Stroke Risk for Nonsteroidal Anti-inflammatory Drugs
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is strengthening an existing warning in prescription drug labels and over-the-counter drug facts labels to indicate that nonsteroidal anti-inflammatory drugs can increase the chance of a heart attack or stroke, either of which can lead to death. Those serious side effects can occur as early as the first few weeks of using an NSAID, and the risk might rise the longer people take NSAIDs.
An Interview With James Blankenship, MD, FSCAI
Cardiac Interventions Today
The newly inducted president of SCAI discusses what's ahead for the society during the next year, challenges with current healthcare policy and why he's an enthusiastic radialist.
FDA Reports Serious Adverse Events With LARIAT Used for LAA Closure
The U.S. Food and Drug Administration issued a safety communication to providers and patients regarding 45 patient deaths and other adverse events associated with SentreHEART devices used for left-atrial-appendage closure, including its LARIAT suture delivery device.
The SentreHEART LARIAT and associated technologies have not been approved by the FDA for the prevention of thromboembolic stroke in patients with atrial fibrillation.
SCAI.15 From Atherectomies to Antiplatelets
Interventional Cardiology's annual meeting, SCAI 2015 Scientific Sessions, took place May 6-9 in San Diego. Here are some highlights from the late-breaking clinical trials.
Reopening the Book on Treating PVCs: More Evidence for PVC-HF Link
A higher percentage of premature ventricular contractions predicted a drop-off in left ventricular ejection fraction and a greater risk of incident heart failure and mortality in a long-term follow-up of >1100 participants in a community-based study. All persons in the analysis had been older than 65 and free of heart failure with a normal left ventricular ejection fraction at baseline when they underwent 24-hour Holter monitoring for PVC assessment.
PCSK9 Inhibitors Versus the Guidelines
With cardiovascular disease prevention guidelines controversially having dropped lipid targets in 2013 and instead emphasizing statins for all at-risk people with elevated levels, where does a new class fit that dramatically lowers low-density lipoproteins beyond what statins can do? The two PCSK9 inhibitors recommended for approval by U.S. Food and Drug Administration advisers last month — evolocumab (Repatha) and alirocumab (Praluent) — have cut low-density lipoproteins by an absolute 30 to 60 percent from baseline across trials, either on top of a statin or alone depending on the population.
Registry Data Challenge CABG Survival Advantage in Diabetics Versus PCI Using Contemporary Stents
In patients with diabetes mellitus and multivessel disease, percutaneous coronary intervention with a current-generation stent is associated with a lower risk of death and stroke in early follow-up but an equivalent risk of death and a higher rate of myocardial infarction and need for repeat revascularizations in the long term when compared with coronary artery bypass graft surgery. These are the main findings from an analysis of more than 16,000 patients included in the New York state percutaneous coronary intervention and cardiac surgery registries.
The Summer of Cardiology Blockbusters?
U.S. Food and Drug Administration approval of heart failure drug sacubitril/valsartan (Entresto), previously known as LCZ696, and the pending approval of two PCSK9 inhibitors this summer has reinvigorated the search for further advances in cardiology, experts said. Pharmacologic findings with major impact on clinical practice have otherwise been sparse, noted Milton Packer, MD, chair of clinical sciences at UT Southwestern in Dallas and lead researcher on the PARADIGM-HF trial of LCZ696.
Cardiology Today Offers Resource Featuring Top Findings, Clinical Perspectives From the SCAI Scientific Sessions
Cardiology Today has released an interactive online supplement that compiles top research from the annual Society for Cardiovascular Angiography and Interventions Scientific Sessions in San Diego and offers expert perspectives to put key findings into context for practitioners. This resource covers encouraging data revealed on the combination of blood pressure and cholesterol therapies to reduce coronary plaque in the MILLION study, as well as the transition off dual antiplatelet therapy with cilostazol in the OUTSIDE START study.
For a complete list of job postings, click here.
To post your resume, click here.
||SCAI Fellows Course at LWSIC
||SCAI TAVR Session @ SOLACI
||Mexico City, MEXICO
||SCAI China Fellows Course
||SCAI CPVI - Complex Peripheral Vascular Interventions
SCAI at Great Wall International Congress of Cardiology
SCAI Fellows Course at AICT 2015
||SCAI 2015 Fall Fellows Courses
||SCAI Session at CardioEgypt 2016
|May 4-7, 2016
||SCAI 2016 Scientific Sessions
CLICK HERE for a full calendar of SCAI events
The news summaries appearing in SCAI This Week are based on original information from news organizations and are produced by Multibriefs, an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI This Week constitute the official opinion of SCAI.
The SCAI This Week news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI This Week may be directed to Multibriefs at email@example.com.
Missed last week's issue? See which articles your colleagues read most.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063